Partnership / Collaboration · Southeast Asia · Announced 17 Sept 2026
Eva Pharma → CCL Pharmaceuticals
Partnership / Collaboration deal between Eva Pharma (Egypt) and CCL Pharmaceuticals (Pakistan), announced 17 Sept 2026. Value: Undisclosed.
Parties: Eva Pharma (Egypt) → CCL Pharmaceuticals (Pakistan)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- Select Central Asia + Southeast Asia markets
- Therapeutic area
- Metabolic / Diabetes
- Asset
- GLP-1 therapies (metabolic)
- Announced
- 17 Sept 2026
Our analysis
Almost every deal in our tracker flows into MENA (the world supplies; MENA consolidates).
This flows outward from MENA into Asia: an Egyptian originator (EVA) using a Pakistani partner (CCL) to reach Central Asia and Southeast Asia. It's EVA explicitly executing a strategy to grow beyond its Middle East & Africa base — the same outward-expansion ambition we've tracked in AUG and Pharco , but pointed east rather than into the Gulf, and in the hottest therapeutic class on earth.
The full analysis is free to read with a work email on this page.
Source: CCL Pharmaceuticals announcement